Drug Profile


Alternative Names: JNJ-42756493; JNJ-493

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Developer Janssen Research & Development
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
  • Phase I/II Hepatocellular carcinoma; Lymphoma; Solid tumours
  • Phase I Cancer
  • Preclinical Multiple myeloma

Most Recent Events

  • 23 Feb 2017 Janssen Research & Development and Celerion plans a phase I trial in Healthy volunteers in USA (PO) (NCT03066687)
  • 31 Oct 2016 Preclinical trials in Multiple myeloma in Belgium (PO) before October 2016
  • 31 Oct 2016 University Health Network, Toronto plans a phase II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada (PO) (NCT02952573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top